Research programme: bivalent typhoid vaccine - Novartis Vaccines Institute for Global HealthAlternative Names: Bivalent Salmonella typhi/Salmonella paratyphi vaccine - NVGH; Bivalent typhoid vaccine - Novartis; Combined typhoid-paratyphoid vaccine - Novartis; Dual-acting typhoid vaccine - Novartis; Salmonella bivalent typhi/paratyphi A vaccine - NVGH
Latest Information Update: 16 Jul 2016
At a glance
- Originator Novartis Vaccines Institute for Global Health
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Typhoid